SCHEMBL7560941

SCHEMBL7560941

O=C1NCC=CN1C(=O)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.52
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
NAMPT P43490 1/20 0.46
RAB9A P51151 4/20 0.45
LMNA P02545 2/20 0.44
TGM2 P21980 1/20 0.43
NPC1 O15118 4/20 0.43
MAPT P10636 4/20 0.43
MAPK1 P28482 2/20 0.43
MITF O75030 1/20 0.43
POLB P06746 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MYOC Q99972 1/20 0.43
APEX1 P27695 1/20 0.42
HSPA9 P38646 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7258861 0.72 GAA (0.74) GAAMEN1KMT2ANAMPTRAB9A
SCHEMBL28813844 0.72 GAA (0.85) GAAMEN1KMT2ANAMPTRAB9A
SCHEMBL9771580 0.70 GAA (0.55) GAAMEN1KMT2ANAMPTRAB9A
SCHEMBL14574134 0.70 GAA (0.97) GAAMEN1KMT2ARAB9ALMNA
SCHEMBL5311792 0.70 SIRT6 (0.49) GAAMEN1KMT2ARAB9ALMNA
SCHEMBL9435700 0.69 GAA (1.00) GAAMEN1KMT2ARAB9ALMNA
SCHEMBL6302157 0.68 MEN1 (1.00) GAAMEN1KMT2ANAMPTRAB9A
SCHEMBL1177730 0.68 MEN1 (1.00) GAAMEN1KMT2ANAMPTRAB9A
SCHEMBL4315881 0.68 LMNA (0.66) GAAMEN1KMT2ANAMPTRAB9A
SCHEMBL3710550 0.67 MEN1 (0.82) GAAMEN1KMT2ANAMPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020010186-A1 Dihydropyrimidines and uses thereof SYNAPTIC PHARMACEUTICAL CORPORATION 2002-01-24 US disclosed
US-6245773-B1 BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE SYNAPTIC PHARMACEUTICAL CORPORATION 2001-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010186-A1 Dihydropyrimidines and uses thereof QDPR, DPYD, ADRA1D GAA 2115/4885MEN1 2855/4885KMT2A 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.